Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.68 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.68 |
| ▸ | MGLL | Q99685 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17444083 | 0.93 | OPRM1 (0.63) | OPRM1OPRL1 | |
| SCHEMBL17444269 | 0.89 | OPRM1 (0.58) | OPRM1OPRL1CHRM2 | |
| SCHEMBL17439016 | 0.86 | OPRM1 (0.71) | OPRM1OPRL1OPRK1HSD11B1 | |
| SCHEMBL19159719 | 0.86 | MGLL (0.66) | MGLLHRH3CHRM2CHRM3 | |
| SCHEMBL17438840 | 0.84 | OPRM1 (0.68) | OPRM1OPRL1OPRK1HSD11B1 | |
| SCHEMBL17444409 | 0.83 | OPRM1 (0.60) | OPRM1OPRL1 | |
| SCHEMBL17443958 | 0.83 | OPRL1 (0.60) | OPRM1OPRL1OPRK1 | |
| SCHEMBL17444302 | 0.83 | OPRM1 (0.54) | OPRM1OPRL1MGLLHRH3 | |
| SCHEMBL17438816 | 0.83 | OPRM1 (0.67) | OPRM1OPRL1OPRK1HSD11B1 | |
| SCHEMBL17444263 | 0.82 | OPRM1 (0.59) | OPRM1OPRL1OPRK1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169666-B1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-06-06 | — | — | EP | claimed |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | claimed |
| EP-3169666-A1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | claimed |
| WO-2016008582-A1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | OPRM1 2/4885OPRL1 1/4885MGLL 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.